Pages that link to "Q39419773"
Jump to navigation
Jump to search
The following pages link to Success and problems of long-term levodopa therapy in Parkinson's disease (Q39419773):
Displaying 50 items.
- A Brief History of Pallidotomy (Q22242789) (← links)
- Preservation of function in Parkinson's disease: What's learning got to do with it? (Q26853387) (← links)
- Stem cell-based approach for the treatment of Parkinson's disease (Q27004330) (← links)
- Expanding frontiers in weight-control research explored by young investigators (Q28077983) (← links)
- Prospects for new restorative and neuroprotective treatments in Parkinson's disease (Q28138668) (← links)
- Shattuck lecture--neurodegenerative diseases and prions (Q28189500) (← links)
- Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa (Q28201762) (← links)
- GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets (Q31900813) (← links)
- Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation (Q32134305) (← links)
- Tests to assess motor phenotype in mice: a user's guide (Q33464903) (← links)
- Surgical options in Parkinson's disease (Q33545304) (← links)
- Age influences magnitude but not duration of response to levodopa (Q33590439) (← links)
- RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1 (Q33607305) (← links)
- Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease (Q33628439) (← links)
- Repair of the damaged brain. The Alfred Meyer Memorial Lecture 1998. (Q33774931) (← links)
- Neuropsychiatric aspects of Parkinson's disease (Q33832479) (← links)
- Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson's disease: a review of the literature (Q33832672) (← links)
- Asymmetrical lateral ventricular enlargement in Parkinson's disease. (Q34012649) (← links)
- Levodopa motor complications in Parkinson's disease (Q34070854) (← links)
- Modulation of habit formation by levodopa in Parkinson's disease (Q34081731) (← links)
- Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss (Q34116613) (← links)
- The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats (Q34195512) (← links)
- Development of allosteric modulators of GPCRs for treatment of CNS disorders (Q34373958) (← links)
- Clinical spectrum of levodopa-induced complications (Q34452721) (← links)
- Neuroprotection for Parkinson's disease: a new approach for a new millennium (Q34481778) (← links)
- Psychometric Properties of Activity, Self-Efficacy, and Quality-of-Life Measures in Individuals with Parkinson Disease (Q34506349) (← links)
- Gene therapy for Parkinson's disease (Q34534274) (← links)
- Dystonia and dyskinesia (Q34744720) (← links)
- Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core. (Q34785967) (← links)
- Do neurologists in Germany adhere to the national Parkinson's disease guideline? (Q34879044) (← links)
- Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. (Q35129374) (← links)
- Neuroprotective strategies in Parkinson's disease : an update on progress (Q35182054) (← links)
- Prevention and treatment of motor fluctuations (Q35198070) (← links)
- The functional role of mesotelencephalic dopamine systems (Q35273641) (← links)
- Cognitive outcome after unilateral pallidal stimulation in Parkinson's disease (Q35450152) (← links)
- The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease (Q35456745) (← links)
- Anaesthesia in elderly patients with neurodegenerative disorders: special considerations (Q35687094) (← links)
- Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease (Q35821201) (← links)
- Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease (Q35868420) (← links)
- A novel insulinotropic mechanism of whole grain-derived γ-oryzanol via the suppression of local dopamine D2 receptor signalling in mouse islet (Q36036244) (← links)
- The use of thalamotomy in the treatment of levodopa-induced dyskinesia (Q36085030) (← links)
- Clinical experience with the novel levodopa formulation entacapone levodopa carbidopa (Stalevo). (Q36107140) (← links)
- Entacapone in the treatment of Parkinson's disease (Q36134208) (← links)
- Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons (Q36169973) (← links)
- Cognitive functioning after pallidotomy for refractory Parkinson's disease (Q36318559) (← links)
- Interaction of pergolide with central dopaminergic receptors (Q36395455) (← links)
- Periodontal health and caries prevalence evaluation in patients affected by Parkinson's disease (Q36516071) (← links)
- Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications (Q36542313) (← links)
- Surgery insight: Deep brain stimulation for movement disorders (Q36577302) (← links)
- Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease (Q36577320) (← links)